KA/EN
Register
Medicines reference
Search
Search
Product

Biocan Novel DHPPi

Favourites

Canine distemper virus + Canine adenovirus + Canine parvovirus + Canine parainfluenza virus · Bioveta a.s.

1 form: suspension. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Form Species Dose Frequency Georgia
Suspension · Dog Dog 1 ml
Reconstitute and inject the entire 1 ml dose subcutaneously. Give two doses 3-4 weeks apart from 6 weeks of age. Revaccinate every 3 years for CDV/CAV/CPV and annually for parainfluenza. Vaccinate clinically healthy animals only; maternal antibodies may delay response. Not recommended during pregnancy or lactation. Recently vaccinated dogs may shed vaccine strains; separate them from susceptible non-dog carnivores and cats and dispose of faeces hygienically.
 · two doses 3-4 weeks apart, then component-specific revaccination		 two doses 3-4 weeks apart, then component-specific revaccination Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბიოკან ნოველ DHPPi
№ 118-11
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Biocan Novel DHPPi, Suspension

lyophilisate and solvent for injection, 1 ml dose for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.3/10
Very good
vetman assessment

Biocan Novel DHPPi

lyophilisate and solvent for injection, 1 ml dose for dogs
Assessed clinical scopeDog · Full dog label from 6 weeks: prevent or reduce mortality, signs, leukopenia and viral shedding caused by CDV, CAV-1/2, CPV and CPiV according to each component claim · Subcutaneous
Care settingPreventive veterinary vaccination with examination, cold-chain control and emergency treatment available
vetman score 8.3/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 118-11 · Verified on 21 Oct 2026

A strong, transparent core-plus-parainfluenza vaccine with useful long core duration. Its two-dose label minimum must still be fitted into a modern puppy programme that finishes the core series at 16 weeks or later when maternal antibody is relevant.

Regulatory and scientific credibility9.0/10

The exact one-dose presentation is registered in Georgia and has a current regulator-hosted EU product record and detailed SPC with transparent strains, potency, schedule and duration-of-immunity claims.

Clinical efficacy8.0/10

The live CDV, CAV and CPV core components have strong consensus support and the label documents three-year protection; CPiV is useful but annual and risk-based, while maternal antibody can still require a later puppy dose than the two-dose minimum label course.

Safety and tolerability8.0/10

The benefit-risk is favourable in healthy dogs; transient injection-site swelling is common and gastrointestinal or hypersensitivity reactions are rare, while live-strain shedding and reproductive restrictions require attention.

Clinical practicality8.0/10

A fixed 1 ml subcutaneous dose and three-year core revaccination are practical; reconstitution, immediate use, cold chain, annual CPiV decisions and age-appropriate completion of the puppy series add manageable work.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in hypersensitivity to an excipient; vaccinate clinically healthy dogs only.
  • Maternal antibody can delay response. Fit the label course into a puppy series with the final core dose at 16 weeks or later when exposure and maternal-antibody risk warrant it.
  • Safety during pregnancy and lactation is not established and use is not recommended.
  • Vaccinated dogs can shed live CAV-2, CPiV and CPV-2b strains. Keep susceptible non-dog carnivores and cats away and dispose of faeces hygienically.
  • No safety or efficacy information is available for use with other veterinary medicines; decide pre- or post-treatment timing case by case and do not mix unless specifically authorised.
  • Transient injection-site swelling is common; rare gastrointestinal or hypersensitivity reactions require observation and immediate symptomatic treatment when indicated.
  • Store and transport at 2-8°C, do not freeze, protect from light and use the reconstituted dose immediately.
Assessment sources
  1. EU UPD Biocan DHPPi2026
  2. WSAVA vaccination 20242024
  3. AAHA canine vaccination 20222022
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Canine distemper virus3.1 log10 TCID50/dose Canine adenovirus3.6 log10 TCID50/dose Canine parvovirus4.3 log10 TCID50/dose Canine parainfluenza virus3.1 log10 TCID50/dose
Formulation Type
Suspension
Administration route
Subcutaneous
Manufacturer
Bioveta a.s. · Czechia
Manufacturer (register)
Bioveta a.s., Czechia
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 437, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბიოკან ნოველ DHPPi
№ 118-11
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown
DoseSpeciesWeightRouteFrequencySource
1 ml
Reconstitute and inject the entire 1 ml dose subcutaneously. Give two doses 3-4 weeks apart from 6 weeks of age. Revaccinate every 3 years for CDV/CAV/CPV and annually for parainfluenza. Vaccinate clinically healthy animals only; maternal antibodies may delay response. Not recommended during pregnancy or lactation. Recently vaccinated dogs may shed vaccine strains; separate them from susceptible non-dog carnivores and cats and dispose of faeces hygienically.
 Dog Any weight Subcutaneous two doses 3-4 weeks apart, then component-specific revaccination
EU UPD Biocan DHPPi
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Biocan Novel DHPPi - official product information
EU Union Product Database, 2026

Canine distemper virus: No dose supported by a publicly verifiable source yet

Canine adenovirus: No dose supported by a publicly verifiable source yet

Canine parvovirus: No dose supported by a publicly verifiable source yet

Canine parainfluenza virus: No dose supported by a publicly verifiable source yet

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 21 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗